0001770252-21-000009.txt : 20210923
0001770252-21-000009.hdr.sgml : 20210923
20210923172440
ACCESSION NUMBER: 0001770252-21-000009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210921
FILED AS OF DATE: 20210923
DATE AS OF CHANGE: 20210923
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lambert Nicole
CENTRAL INDEX KEY: 0001770252
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26642
FILM NUMBER: 211273303
MAIL ADDRESS:
STREET 1: 320 WAKARA WAY
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MYRIAD GENETICS INC
CENTRAL INDEX KEY: 0000899923
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 870494517
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 320 WAKARA WAY
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
BUSINESS PHONE: 801-584-3600
MAIL ADDRESS:
STREET 1: 320 WAKARA WAY
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2021-09-21
0
0000899923
MYRIAD GENETICS INC
MYGN
0001770252
Lambert Nicole
320 WAKARA WAY
SALT LAKE CITY
UT
84108
0
1
0
0
See Remarks
Common Stock
2021-09-21
4
A
0
65870
0.0
A
192921
D
Consists of performance-based restricted stock units (PSUs) granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. The PSUs were initially granted on October 8, 2020, subject to accomplishment of pre-determined performance metrics. On September 21, 2021, the Compensation and Human Capital Committee determined the final award amount based on the accomplishment of the applicable performance metrics. Each PSU represents a contingent right to receive one share of the Company's common stock, and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024.
Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.
By: Nathan A. Smith For: Nicole Lambert
2021-09-23